APIIC Releases Recommendations to Combat Rising U.S. Drug Shortages and Ensure Access to Life-Saving Medications
“The collaboration necessary to develop a paper of this caliber is impressive,” said Tony Sardella, chair of the API Innovation Center.
- “The collaboration necessary to develop a paper of this caliber is impressive,” said Tony Sardella, chair of the API Innovation Center.
- The APIIC report encourages pharmaceutical manufacturers and policy makers to address these vulnerabilities to national health security through the adoption of advanced biomanufacturing technologies and public incentive programs designed to reignite idle capacity at U.S. manufacturing facilities.
- “For more than 200 years, U.S. Pharmacopeia has brought healthcare professionals, scientists, and regulators together to ensure quality and trust in our drugs,” said Dennis Hall, vice president, Advanced Manufacturing Technologies at U.S. Pharmacopeia (USP).
- It follows developments and reports from the White House Office of Science and Technology , the National Economic Council (NEC) Director and the National Security Advisor (NSA), calling for a new approach aimed at guaranteeing Americans reliable access to essential medications.